loading page

Influenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021–22 I-MOVE primary care multicentre study
  • +32
  • Esther Kissling,
  • Francisco Pozo,
  • Iván Martínez-Baz,
  • Silke Buda,
  • Ana-Maria Vilcu,
  • Lisa Domegan,
  • Clara Mazagatos Ateca,
  • Frederika Dijkstra,
  • Neus Latorre-Margalef,
  • Sanja Kurečić Filipovićović,
  • Ausenda Machado,
  • Mihaela Lazar,
  • Itziar Casado Buesa,
  • Ralf Dürrwald,
  • Sylvie van der Werf,
  • Joan O'Donnell,
  • Juan Antonio Linares Dopido,
  • Adam Meijer,
  • Maximilian Riess,
  • Vesna Višekruna Vučina,
  • Ana Paula Rodrigues,
  • Maria Elena Mihai,
  • Jesus Castilla,
  • Luise Goerlitz,
  • Alessandra Falchi,
  • Jeff Connell,
  • Daniel Castrillejo,
  • Mariette Hooiveld,
  • AnnaSara Carnahan,
  • Maja Ilić,
  • Raquel Guiomar,
  • Alina-Elena Ivanciuc,
  • Marine Maurel,
  • Ajibola Omokanye,
  • Marta Valenciano
Esther Kissling
Epiconcept

Corresponding Author:e.kissling@epiconcept.fr

Author Profile
Francisco Pozo
Instituto de Salud Carlos III
Author Profile
Iván Martínez-Baz
. Instituto de Salud Pública de Navarra - IdiSNA
Author Profile
Silke Buda
Robert Koch-Institute
Author Profile
Ana-Maria Vilcu
Sorbonne Universités, UPMC Univ Paris 06, INSERM
Author Profile
Lisa Domegan
Health Service Executive-Health Protection Surveillance Centre
Author Profile
Clara Mazagatos Ateca
Institute of Health Carlos III
Author Profile
Frederika Dijkstra
National Institute for Public Health and the Environment (RIVM)
Author Profile
Neus Latorre-Margalef
The Public Health Agency of Sweden
Author Profile
Sanja Kurečić Filipovićović
Croatian Institute of Public Health
Author Profile
Ausenda Machado
Instituto Nacional de Saúde Dr. Ricardo Jorge
Author Profile
Mihaela Lazar
"Cantacuzino" National Military Medical Institute for Research and Development
Author Profile
Itziar Casado Buesa
Instituto de Salud Pública de Navarra - IdiSNA
Author Profile
Ralf Dürrwald
Robert Koch Institut
Author Profile
Sylvie van der Werf
Institut Pasteur
Author Profile
Joan O'Donnell
Health Service Executive-Health Protection Surveillance Centre
Author Profile
Juan Antonio Linares Dopido
Subdirección de Epidemiología, Dirección General de Salud Pública, Servicio Extremeño de Salud
Author Profile
Adam Meijer
National Institute for Public Health and the Environment (RIVM)
Author Profile
Maximilian Riess
The Public Health Agency of Sweden
Author Profile
Vesna Višekruna Vučina
Croatian Institute of Public Health
Author Profile
Ana Paula Rodrigues
Instituto Nacional de Saúde Dr. Ricardo Jorge
Author Profile
Maria Elena Mihai
"Cantacuzino" National Military Medical Institute for Research and Development
Author Profile
Jesus Castilla
Instituto de Salud Pública de Navarra - IdiSNA
Author Profile
Luise Goerlitz
Robert Koch Institut
Author Profile
Alessandra Falchi
Laboratoire de Virologie, Université de Corse-Inserm
Author Profile
Jeff Connell
National Virus Reference Laboratory, University College Dublin
Author Profile
Daniel Castrillejo
Servicio de Epidemiología, DGSP, Consejería de Políticas Sociales, Salud Pública y Bienestar Animal
Author Profile
Mariette Hooiveld
NIVEL
Author Profile
AnnaSara Carnahan
The Public Health Agency of Sweden
Author Profile
Maja Ilić
Croatian Institute of Public Health
Author Profile
Raquel Guiomar
Instituto Nacional de Saúde Dr. Ricardo Jorge
Author Profile
Alina-Elena Ivanciuc
"Cantacuzino" National Military Medical Institute for Research and Development
Author Profile
Marine Maurel
Epiconcept
Author Profile
Ajibola Omokanye
European Centre for Disease Prevention and Control
Author Profile
Marta Valenciano
Epiconcept
Author Profile

Abstract

Background: In 2021–22, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11,000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95%CI: 43–89) and 81% (95%CI: 44–93) among those aged 15–64 years. Overall VE against influenza A(H3N2) was 29% (95%CI: 12–42) and 25% (95%CI: -41–61), 33% (95%CI: 14–49) and 26% (95% CI: -22 to 55) among those aged 0–14, 15–64 and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95%CI: -6–39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but 8 belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021–22 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.
20 Oct 2022Submitted to Influenza and other respiratory viruses
21 Oct 2022Submission Checks Completed
21 Oct 2022Assigned to Editor
25 Oct 2022Editorial Decision: Revise Minor
25 Oct 20221st Revision Received
27 Oct 2022Submission Checks Completed
27 Oct 2022Assigned to Editor
29 Oct 2022Editorial Decision: Accept